Horizon Europe is the European Union (EU) funding programme for the period 2021 – 2027, which targets the sectors of research and innovation. The programme’s budget is around € 95.5 billion, of which € 5.4 billion is from NextGenerationEU to stimulate recovery and strengthen the EU’s resilience in the future, and € 4.5 billion is additional aid.
Ageing, the gradual decline of organismal homeostasis and of physiologic functions throughout the body and mind, is a critical shared risk factor for many ageing-related chronic diseases. The EU also has an ageing society – by 2050, the share of 85+ year-olds in the EU is expected to more than double, but extended life expectancy is not matched with years spent in good health, which currently stands at 70.5 years. This will present significant social, economic and healthcare challenges and thus calls for interventions that will promote healthy longevity, as well as tools that will enable the adoption of these interventions.
Over the past decades basic research has identified hallmarks and cellular mechanisms of ageing, creating the basis for biotechnology-based or pharmaceutical therapeutic interventions, such as targeting cellular maintenance pathways, stem cell exhaustion, cellular senescence or metabolic fitness. Nonetheless, translating these insights into clinical interventions has had a low success rate, partially due to the difficulty of:
This Challenge therefore looks to translate decades of ageing research into tangible biopharmaceutical solutions for healthy ageing
Portfolio approach
The portfolio of projects selected under this Challenge will ensure a coverage of projects developing interventions, biomarkers and NAMs, considering the following guidelines for portfolio composition:
The selected consortia will benefit from mutual learning, and the exchange of expertise. Consortia will be encouraged to collaborate to address the following shared challenges faced by all ageing interventions:
Applicants to this Challenge will be expected to develop a proof of concept in one of the following three areas:
Precision nutrition, the development of novel ageing clocks and wellness applications fall outside the scope of this Challenge.
All proposals should consider biological sex and gender-specific health determinants in their development, with reproductive ageing also in scope.
100%
Expected EU contribution per project: between €500.000 and €4.000.000
The admissibility and eligibility conditions are described in Annex 2 and Annex 3 of the EIC Work Programme 2026.
In order to apply, proposals must meet the general eligibility requirements (see Annex 2 of Work Programme) as well as possible specific eligibility requirements for a specific Challenge.
The EIC Pathfinder Challenges can support projects from consortia or from single legal entities.
Consortia of two entities must be comprised of independent legal entities from two different Member States or Associated Countries.Consortia of 3 or more entities must include as beneficiaries at least 3 legal entities, independent from each other and each established in a different country as follows:
If the proposal is from one single legal entity, this entity must be established in a Member State or an Associated Country (unless stated otherwise in the specific Challenge chapter).
The legal entities may for example be universities, research organisations, SMEs, startups, natural persons. In the case of single beneficiary projects, mid-caps and larger companies will not be permitted.
Research and Innovation Foundation
Address: 29a Andrea Michalakopoulou, 1075 Nicosia, P.B. 23422, 1683 Nicosia
Telephone: +357 22205000
Fax: +357 22205001
Email: support@research.org.cy
Website: https://www.research.org.cy/en/
Contact Person:
Dr. Leda Skoufari – Themistou
Senior Scientific Officer
Email: leda@research.org.cy
Research Enquiry Service: https://ec.europa.eu/info/research-and-innovation/contact/research-enquiry-service_en